Jared Gollob Sells 59,576 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Jared Gollob sold 59,576 shares of the firm’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $61.42, for a total transaction of $3,659,157.92. Following the completion of the transaction, the insider directly owned 109,992 shares of the company’s stock, valued at approximately $6,755,708.64. The trade was a 35.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Jared Gollob also recently made the following trade(s):

• On Monday, October 13th, Jared Gollob sold 3,114 shares of Kymera Therapeutics stock. The shares were sold at an average price of $60.00, for a total transaction of $186,840.00.

Kymera Therapeutics Stock Performance

Kymera Therapeutics stock opened at $60.46 on Friday. The firm’s fifty day moving average price is $48.45 and its 200-day moving average price is $41.03. The stock has a market cap of $4.32 billion, a P/E ratio of -17.42 and a beta of 2.26. Kymera Therapeutics, Inc. has a fifty-two week low of $19.44 and a fifty-two week high of $63.96.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The company had revenue of $11.48 million for the quarter, compared to analysts’ expectations of $17.37 million. Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The business’s quarterly revenue was down 55.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.58) EPS. On average, analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Hedge Funds Weigh In On Kymera Therapeutics

A number of large investors have recently made changes to their positions in KYMR. Farther Finance Advisors LLC boosted its stake in shares of Kymera Therapeutics by 642.9% during the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock worth $27,000 after purchasing an additional 540 shares during the period. PNC Financial Services Group Inc. boosted its stake in shares of Kymera Therapeutics by 506.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after purchasing an additional 770 shares during the period. Osaic Holdings Inc. boosted its stake in shares of Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in shares of Kymera Therapeutics during the 1st quarter worth about $68,000. Finally, KBC Group NV boosted its stake in shares of Kymera Therapeutics by 15.2% during the 1st quarter. KBC Group NV now owns 2,479 shares of the company’s stock worth $68,000 after purchasing an additional 328 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on KYMR shares. Wall Street Zen lowered shares of Kymera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 16th. BTIG Research reiterated a “buy” rating and issued a $59.00 target price on shares of Kymera Therapeutics in a research note on Thursday, June 26th. Royal Bank Of Canada began coverage on shares of Kymera Therapeutics in a research note on Tuesday, September 16th. They issued an “outperform” rating and a $70.00 target price on the stock. Jefferies Financial Group set a $64.00 price target on shares of Kymera Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, June 25th. Finally, Wells Fargo & Company reduced their price objective on shares of Kymera Therapeutics from $57.00 to $53.00 and set an “overweight” rating for the company in a research note on Thursday, June 26th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Kymera Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $61.26.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.